With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With ...

A series of recommended shots that health providers administer to children as they age has been a recent target of President Donald Trump and his administration.

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 4 study titled ‘A Phase 4 Study Using a ...

Eligibility for this vaccination is suddenly a timely question. A senior health editor reports on her real-time experience.

Pneumococcal disease poses a severe risk to Indian adults, particularly those with chronic health issues. Despite effective ...

Electronic medical records of 42 children with SCD diagnosed between 2009 and 2023 were retrospectively reviewed. Clinical demographic data and pneumococcal serologies were analysed. Of the 42 ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 STRIDE-13 trial evaluating CAPVAXIVE® (Pneumococcal 21-valent Conjugate ...

Dear Savvy Senior, With a longtime vaccine critic leading the nation’s health departments, can you give me updated ...

Merck & Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical ...

While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.

Infectious disease researchers found the vaccine, used to prevent herpes zoster, or shingles, is also linked to lower risks ...